Goldman Sachs’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Goldman Sachs’s Portfolio CYTH Stock Details CYTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,283	Closed	-$45K	–	6411
2020 Q4	$45K	Buy	+10,283	New	+$48.3K	﹤0.01%	5392

Other funds holding CYTH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

Goldman Sachs's CYTH Position: Q1 2021 in Review

Goldman Sachs sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2021, closing a stake of 10,283 shares — an estimated $45K sold.

Goldman Sachs first reported a position in CYTH in Q4 2020 and held it in 1 quarter. The position peaked at $45K in Q4 2020. 9 funds tracked by Wall St. Rank hold CYTH as of Q1 2021.

Goldman Sachs reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Goldman Sachs sold 10,283 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $45K.
Goldman Sachs first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Goldman Sachs's Cyclo Therapeutics, Inc. Common Stock position peaked at $45K in Q4 2020.
9 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Goldman Sachs's 13F filing for Q1 2021, filed 17 May 2021.